Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONFIRM: Nivolumab in Relapsed Mesothelioma
2016-003111-35Phase 3Unknown
- Sponsor
- University of Southampton
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of nivolumab in mesothelioma, sponsored by University of Southampton. Status: unknown.
02
Drugs
03
Conditions
mesothelioma
Beyond the preview
Go deeper on 2016-003111-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003111-35.